Trial reportEuropean radiology2026
Radiofrequency ablation for patients with primary hyperparathyroidism: a multicenter non-randomized open-label single-arm prospective clinical trial.
Trial report in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Radiofrequency ablation as an alternative treatment for hyperparathyroidism: a case study of a single parathyroid adenoma and review of the literature.Hormones (Athens, Greece) · 2026Review
- Short-term biochemical outcomes after microwave ablation versus parathyroidectomy for primary hyperparathyroidism: an IPTW analysis.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectivesTo evaluate the efficacy, safety, and factors influencing the response to radiofrequency ablation (RFA) in patients with primary hyperparathyroidism (PHPT) in a prospective multicenter trial. MATERIALS AND
methodsBetween September 2022 and June 2024, 34 patients with 35 parathyroid lesions who either refused surgery or were ineligible for it underwent RFA for treatment of PHPT across three hospitals. Nodule size, volume, and biochemical data were compared before and after treatment (at 2 h, 1 week, and 1, 3, 6, and 12 months). Complications were assessed during and after treatment. Factors influencing the treatment response to RFA for PHPT were analyzed.
resultsSignificant reductions in nodule size and volume, as well as improvements in serum parathyroid hormone (PTH) and total calcium levels, were noted at the 3-, 6-, and 12-month follow-ups after RFA (all p < 0.05). Out of the 34 patients, 17 experienced a complete response with normalized serum PTH and calcium levels (50.0%), whereas 17 showed a partial response (50.0%) (median number of sessions 1). The initial serum PTH level was a key factor associated with the treatment response to RFA, with an area under the receiver operating characteristic curve of 0.853 using a PTH cutoff value of ≥ 118 pg/mL. Transient voice change (n = 1) and hypocalcemia (n = 1) were reported after the procedure.
conclusionIn selected cases, RFA is a safe and effective treatment option for patients with PHPT. The initial PTH level of < 118 pg/mL is associated with achieving a biochemical cure after a single treatment. KEY POINTS: Question The efficacy of radiofrequency ablation in treating primary hyperparathyroidism remains unclear due to limited evidence, highlighting the need for further study. Findings In this prospective multicenter study, the complete response rate was 50.0%, with 79.4% achieving normocalcemia. Baseline serum parathyroid hormone levels significantly influenced treatment response. Clinical relevance Radiofrequency ablation is a safe and effective treatment for selected patients with primary hyperparathyroidism, especially those who are ineligible for surgery. Initial serum parathyroid hormone levels predict the likelihood of achieving a biochemical cure after a single treatment.
Indexed as
Identifiers
40715823What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.